Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
therapeutics symbols : Ntla save search
Bavarian Nordic A/S – Notice Convening Annual General Meeting
Published: 2024-03-21 (Crawled : 11:00) - globenewswire.com
GNMSF | News | $289.67 3.83% 5.3K
|
Health Technology
|
| O: 0.03%
H: 3.03%
C: 1.75%
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: 0.14%
H: 0.24%
C: 0.24%
JNJ | News | $149.56 0.3% 0.0% 9.1M
|
Health Technology
|
| O: -0.03%
H: 0.0%
C: 0.0%
SNY | News | $47.69 1.15% 1.13% 1.7M
|
Health Technology
|
| O: 0.3%
H: 0.0%
C: 0.0%
NTLA | $21.535 -1.35% -1.37% 850K
|
Health Technology
|
| O: 2.12%
H: 0.6%
C: -2.54%
GMAB | News | $28.54 -1.48% -1.51% 560K
|
Health Technology
|
| O: 1.19%
H: 0.47%
C: -0.77%
meeting
Intellia Therapeutics Announces First Patient Dosed in the Phase 3 MAGNITUDE Study of NTLA-2001 as a Single-Dose CRISPR-Based Treatment for Transthyretin Amyloidosis with Cardiomyopathy
Published: 2024-03-18 (Crawled : 12:00) - globenewswire.com
NTLA | $21.535 -1.35% -1.37% 850K
|
Health Technology
|
| O: -0.88%
H: 0.0%
C: -2.42%
ntla-2001 first treatment therapeutics study
Intellia Therapeutics and ReCode Therapeutics Announce Strategic Collaboration to Develop Novel Gene Editing Therapies for Cystic Fibrosis
Published: 2024-02-15 (Crawled : 12:30) - globenewswire.com
NTLA | $21.535 -1.35% -1.37% 850K
|
Health Technology
|
| O: -1.17%
H: 5.15%
C: 1.86%
fibrosis collaboration therapeutics
Intellia Therapeutics to Hold Conference Call to Discuss Fourth Quarter and Full-Year 2023 Earnings and Company Updates
Published: 2024-02-14 (Crawled : 13:00) - globenewswire.com
NTLA | $21.535 -1.35% -1.37% 850K
|
Health Technology
|
| O: 2.5%
H: 4.5%
C: 4.32%
conference company therapeutics
Intellia Therapeutics Announces Publication of Positive Interim Phase 1 Data for NTLA-2002 in Patients with Hereditary Angioedema in the New England Journal of Medicine
Published: 2024-01-31 (Crawled : 22:00) - globenewswire.com
NTLA | $21.535 -1.35% -1.37% 850K
|
Health Technology
|
| O: 0.88%
H: 8.11%
C: 5.12%
ntla-2002 positive publication therapeutics
SparingVision Reaches Final Dose Escalation Step in PRODYGY Trial with SPVN06 for retinitis pigmentosa
Published: 2024-01-24 (Crawled : 00:00) - biospace.com/
NTLA | $21.535 -1.35% -1.37% 850K
|
Health Technology
|
| O: 1.28%
H: 1.0%
C: -4.06%
spvn06 trial
Valo Health Announces Changes to its Board of Directors and Leadership Team
Published: 2024-01-16 (Crawled : 20:00) - prnewswire.com
AZNCF | News | $138.73 -4.19% 3.7K
|
Health Technology
|
| O: 0.03%
H: 0.75%
C: 0.75%
JNJ | News | $149.56 0.3% 0.0% 9.1M
|
Health Technology
|
| O: -1.02%
H: 0.0%
C: 0.0%
NTLA | $21.535 -1.35% -1.37% 850K
|
Health Technology
|
| O: -2.62%
H: 2.9%
C: -1.23%
AZN | News | $70.85 1.03% 1.02% 5.6M
|
Health Technology
|
| O: -1.81%
H: 0.63%
C: 0.3%
health
Intellia Therapeutics Highlights its Three-Year Strategic Priorities and Anticipated 2024 Key Milestones
Published: 2024-01-04 (Crawled : 21:00) - globenewswire.com
REGN | News | $906.84 0.74% 0.74% 340K
|
Health Technology
|
| O: -0.79%
H: 1.96%
C: 0.9%
NTLA | $21.535 -1.35% -1.37% 850K
|
Health Technology
|
| O: -2.34%
H: 0.45%
C: -0.69%
therapeutics
Intellia Therapeutics Receives European Union Orphan Drug Designation for NTLA-2002, an Investigational In Vivo CRISPR Genome Editing Treatment for Hereditary Angioedema
Published: 2023-11-14 (Crawled : 12:30) - globenewswire.com
NTLA | $21.535 -1.35% -1.37% 850K
|
Health Technology
|
| O: 6.47%
H: 5.29%
C: 4.34%
ntla-2002 drug crispr designation therapeutics
Intellia Therapeutics Announces Third Quarter 2023 Financial Results and Highlights Recent Company Progress
Published: 2023-11-09 (Crawled : 12:30) - globenewswire.com
REGN | News | $906.84 0.74% 0.74% 340K
|
Health Technology
|
| O: -0.89%
H: 0.15%
C: -1.87%
NTLA | $21.535 -1.35% -1.37% 850K
|
Health Technology
|
| O: 0.18%
H: 0.67%
C: -12.42%
company therapeutics financial results
Intellia Presents New Interim Data from the Ongoing Phase 1 Study of NTLA-2001 at the 4th International ATTR Amyloidosis Meeting
Published: 2023-11-02 (Crawled : 11:00) - globenewswire.com
NTLA | $21.535 -1.35% -1.37% 850K
|
Health Technology
|
| O: 2.35%
H: 1.63%
C: 1.46%
ntla-2001 international ongoing meeting study
Regeneron Reports Third Quarter 2023 Financial and Operating Results
Published: 2023-11-02 (Crawled : 11:00) - globenewswire.com
SNY | News | $47.69 1.15% 1.13% 1.7M
|
Health Technology
|
| O: 3.0%
H: 0.0%
C: 0.0%
REGN | News | $906.84 0.74% 0.74% 340K
|
Health Technology
|
| O: 0.08%
H: 4.96%
C: 3.4%
NTLA | $21.535 -1.35% -1.37% 850K
|
Health Technology
|
| O: 2.35%
H: 1.63%
C: 1.46%
ALNY | $146.06 0.19% 0.18% 540K
|
Health Technology
|
| O: 3.4%
H: 0.57%
C: -0.5%
financial results
Intellia Therapeutics to Present Updated Data from Ongoing Phase 1 Study of NTLA-2001 for the Treatment of Transthyretin (ATTR) Amyloidosis and Hold Conference Call to Discuss Third Quarter 2023 Earnings in November
Published: 2023-10-26 (Crawled : 12:00) - globenewswire.com
NTLA | $21.535 -1.35% -1.37% 850K
|
Health Technology
|
| O: 1.31%
H: 4.57%
C: 1.21%
ntla-2001 conference treatment ongoing therapeutics study
Intellia Therapeutics Announces FDA Clearance of Investigational New Drug (IND) Application to Initiate a Pivotal Phase 3 Trial of NTLA-2001 for the Treatment of Transthyretin (ATTR) Amyloidosis with Cardiomyopathy
Published: 2023-10-18 (Crawled : 11:00) - globenewswire.com
NTLA | $21.535 -1.35% -1.37% 850K
|
Health Technology
|
| O: 1.58%
H: 0.44%
C: -5.25%
ntla-2001 fda drug treatment clearance application trial therapeutics
Intellia Therapeutics Receives Priority Medicines (PRIME) Designation From the European Medicines Agency for NTLA-2002, an Investigational In Vivo CRISPR Genome Editing Treatment for Hereditary Angioedema
Published: 2023-10-13 (Crawled : 12:30) - globenewswire.com
NTLA | $21.535 -1.35% -1.37% 850K
|
Health Technology
|
| O: 0.35%
H: 3.41%
C: 2.83%
ntla-2002 crispr treatment designation therapeutics
Regeneron and Intellia Announce Expanded Research Collaboration to Develop CRISPR-Based Therapies for the Treatment of Neurological and Muscular Diseases
Published: 2023-10-03 (Crawled : 11:00) - globenewswire.com
SNY | News | $47.69 1.15% 1.13% 1.7M
|
Health Technology
|
| O: -1.41%
H: 0.0%
C: 0.0%
REGN | News | $906.84 0.74% 0.74% 340K
|
Health Technology
|
| O: -0.74%
H: 0.21%
C: -0.45%
NTLA | $21.535 -1.35% -1.37% 850K
|
Health Technology
|
| O: -0.1%
H: 1.97%
C: 1.02%
treatment research collaboration neurological
Intellia Therapeutics Announces Second Quarter 2023 Financial Results and Highlights Recent Company Progress
Published: 2023-08-03 (Crawled : 12:00) - globenewswire.com
REGN | News | $906.84 0.74% 0.74% 340K
|
Health Technology
|
| O: 2.72%
H: 3.39%
C: 1.24%
NTLA | $21.535 -1.35% -1.37% 850K
|
Health Technology
|
| O: -3.48%
H: 2.74%
C: 1.98%
therapeutics financial results
Intellia Therapeutics to Hold Conference Call to Discuss Second Quarter 2023 Earnings and Company Updates
Published: 2023-07-27 (Crawled : 12:00) - globenewswire.com
NTLA | $21.535 -1.35% -1.37% 850K
|
Health Technology
|
| O: 1.81%
H: 0.33%
C: -4.14%
conference therapeutics
Biotech and Biopharma Executive Eliana Clark Joins Culture Biosciences’ Advisory Board
Published: 2023-07-19 (Crawled : 13:00) - biospace.com/
SNY | News | $47.69 1.15% 1.13% 1.7M
|
Health Technology
|
| O: 0.88%
H: 0.0%
C: 0.0%
NTLA | $21.535 -1.35% -1.37% 850K
|
Health Technology
|
| O: 1.52%
H: 2.56%
C: 1.72%
biotech biopharma
CRISPR Market worth $7.1 billion | MarketsandMarkets
Published: 2023-06-30 (Crawled : 16:00) - prnewswire.com
TMO | News | $574.59 4.78% -1.12% 2.5M
|
Health Technology
|
| O: 0.41%
H: 1.38%
C: 1.02%
DHR | $253.11 7.21% 0.0% 6.8M
|
Health Technology
|
| O: 0.52%
H: 1.09%
C: 0.42%
A | $139.2 3.95% -0.14% 2M
|
Health Technology
|
| O: 0.58%
H: 1.65%
C: 1.28%
TWST | $31.505 6.98% 6.51% 1.1M
|
Health Technology
|
| O: 2.35%
H: 5.54%
C: 2.2%
DTIL | $10.33 6.72% 6.29% 31K
|
Health Technology
|
| O: 0.0%
H: 3.6%
C: 1.15%
NTLA | $21.535 -1.35% -1.37% 850K
|
Health Technology
|
| O: 1.66%
H: 0.76%
C: -1.92%
CRSP | News M | $56.46 1.44% 1.42% 1.2M
|
Health Technology
|
| O: 1.23%
H: 0.49%
C: -2.74%
BEAM | $23.46 -2.66% -2.73% 1.2M
|
Health Technology
|
| O: 1.16%
H: 0.44%
C: -0.78%
crispr market
Gainers vs Losers
| 78% | 22% |
Top 10 Gainers
MTTR | News 4 | $4.6 164.37% 62.17% 28M
|
AGBA | $2.94 135.2% 57.48% 66M
|
Finance
EDBL | News | $6.46 71.81% 41.8% 2M
|
MTC | $2.25 44.23% 30.67% 6M
|
Technology Services
OPRT | News | $3.175 41.11% 29.13% 12M
|
Finance
SHIM | $3.05 35.56% 26.23% 1.1M
|
HKIT | $1.345 31.86% 24.16% 390K
|
Technology Services
ABVC | $1.36 30.77% 23.53% 7.4M
|
Wholesale Trade
OST | $0.512 28.0% 21.88% 290K
|
POET | $1.59 27.2% 21.38% 4.2M
|
Manufacturing
Your saved searches
Save your searches and get alerts when important news are released.